HKSE · 1177.HK
Sino Biopharmaceutical Limited
HK$4.82-HK$0.03 (-0.62%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
Loading market information…
HKSE · 1830.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Perfect Medical Health Management Limited’s quoted price sits in the lower half of its reported 52-week range, 22.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Perfect Medical Health Management Limited’s forward annual dividend is HK$0.14 per share, paid semi-annual. The forward yield is 12.28% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Perfect Medical Health Management Limited’s next earnings report is currently expected on Nov 26, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Perfect Medical Health Management Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as an investment holding firm, Perfect Medical Health Management Limited delivers a comprehensive suite of medical and aesthetic services across Hong Kong, mainland China, Macau, Singapore, and Australia. Its offerings encompass medical aesthetics, hair restoration, pain relief, proactive health management, and fertility treatments. Beyond its core medical provisions, the company is involved in advertising, charitable initiatives, and management services, while also holding trademarks, leasing equipment, and operating a network of service centers. Established in 2003, the company, initially known as Perfect Shape Medical Limited, adopted its current name, Perfect Medical Health Management Limited, in June 2021. Its corporate headquarters are located in Mong Kok, Hong Kong.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:25 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| HK$0.13 |
| HK$722.09M-57.52% vs estimate |
| Q2 2022 | Nov 23, 2022 | HK$0.12 | HK$668.30M-60.69% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$4.82-HK$0.03 (-0.62%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
HK$35.02-HK$2.68 (-7.11%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 29.2% below the high.
HK$2.83+HK$0.07 (+2.54%)
Alibaba Health Information Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
HK$38.70+HK$1.40 (+3.75%)
Fameglow Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 15.28% below the high.
HK$4.64+HK$0.14 (+3.11%)
China Resources Pharmaceutical Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.02% below the high.
HK$16.62+HK$0.42 (+2.59%)
Beauty Farm Medical and Health Industry Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.56% below the high.
HK$0.60HK$0.00 (0.0%)
Green International Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
HK$0.90HK$0.00 (0.0%)
Miricor Enterprises Holdings Ltd’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
